Safety profile of the intravitreal streptokinase-plasmin complex as an adjunct to vitrectomy in the rabbit

Graefes Arch Clin Exp Ophthalmol. 2006 Aug;244(8):996-1002. doi: 10.1007/s00417-005-0159-4. Epub 2005 Dec 20.

Abstract

Background: The generation of an atraumatic posterior vitreous detachment (PVD), a common goal in vitreoretinal surgery, is a challenge, particularly in children and young trauma patients. Plasmin has been proposed as an adjunct to vitrectomy to enzymatically generate a PVD. Low doses of streptokinase-activated plasmin were tested in human pilot studies. This dose-escalation study assesses the safety range of intravitreal human streptokinase-plasmin in rabbits.

Methods: Plasminogen was isolated from human plasma by affinity chromatography, followed by activation with streptokinase (1:1), to generate the streptokinase-plasmin complex. Enzyme doses from 0.1-7 activity units (AU, in 0.1 ml) were injected into the mid-vitreous of 35 eyes; six control eyes were injected with balanced salt solution (BSS, 0.1 ml). Thirty minutes after injection, a two-port vitrectomy was performed. Fundus and slit lamp examinations were performed on days 1 and 7. On days 2 and 7, bright flash electroretinography was performed and compared with preoperative recordings. Some animals receiving higher doses of streptokinase-plasmin (1-7 AU) were followed clinically and with electroretinography for up to 9 months.

Results: A mild-to-moderate inflammatory response was seen in both control and plasmin-treated eyes on day 1, but had disappeared completely by day 7 in most eyes. In the 7 AU group, inflammation was stronger and more protracted. Two of three eyes from this group developed wrinkling of the medullary rays; one of them showed discoloration and traction at the medullary rays in the late follow-up. Electroretinograms (ERGs) of vitrectomized control eyes showed the following changes from preoperative values: 48 h, a-wave -11.10% [no significant (n.s.)], b-wave -14.62% (P=0.046); 7 days, a-wave +9.18% (n.s.), b wave +11.69% (n.s.). For the enzyme-treated eyes: 48 h: a-wave -20.43% (P<0.001), b-wave -9.57% (p<0.001); 7 days: a wave -14.21% (P<0.001), b-wave +2.48% (P<0.001). There was no evidence of dose-dependent ERG changes in enzyme-treated eyes at doses up to 5 AU. Groups of up to 3 AU were investigated by light and transmission electron microscopy, without evidence of toxicity.

Conclusion: Streptokinase-plasmin doses up to 3 AU were found to be safe when injected into rabbit eyes followed by vitrectomy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chromatography, Affinity
  • Combined Modality Therapy
  • Drug Combinations
  • Electroretinography
  • Humans
  • Injections
  • Photic Stimulation
  • Plasminogen / administration & dosage*
  • Plasminogen / adverse effects
  • Plasminogen / isolation & purification
  • Rabbits
  • Retina / drug effects
  • Retina / physiology
  • Streptokinase / administration & dosage*
  • Streptokinase / adverse effects
  • Vitrectomy / adverse effects
  • Vitrectomy / methods*
  • Vitreous Body / drug effects
  • Vitreous Detachment / surgery*

Substances

  • Drug Combinations
  • streptokinase-plasminogen complex
  • Plasminogen
  • Streptokinase